# Peter Borchmann

Source: https://onco.cc/people/peter-borchmann/  
OnCo record `peter-borchmann` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads the German Hodgkin Study Group and HD21, which made BrECADD the most effective and least toxic regimen for advanced Hodgkin lymphoma.

## Summary

Peter Borchmann chairs the German Hodgkin Study Group and was principal investigator of HD21, which showed the brentuximab-based BrECADD regimen is both more effective and less toxic than escalated BEACOPP in advanced-stage Hodgkin lymphoma with 95% three-year progression-free survival, and of HD18, which used PET to reduce treatment from six cycles to four. He leads GHSG trials of immunotherapy in first-line disease.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: hodgkin; ghsg; trialist
- Role: Professor of Medicine and Head of the German Hodgkin Study Group, University Hospital Cologne
- Specialisms: Hodgkin lymphoma; PET-guided therapy; Antibody-drug conjugates; Cooperative-group trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Borchmann%20P%5BAuthor%5D%20Hodgkin

## Connected records

- cancers: [Hodgkin lymphoma](https://onco.cc/cancers/hodgkin-lymphoma/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [FDG PET](https://onco.cc/technologies/fdg-pet/)
- drugs: [Brentuximab vedotin](https://onco.cc/drugs/brentuximab-vedotin/)
- companies: [German Hodgkin Study Group](https://onco.cc/companies/ghsg/)
- institutions: [Uniklinik Köln (CIO)](https://onco.cc/institutions/uniklinik-koeln/)
- trials: [GHSG HD10](https://onco.cc/trials/hd10/), [GHSG HD16](https://onco.cc/trials/hd16/), [GHSG HD18](https://onco.cc/trials/hd18/), [GHSG HD21](https://onco.cc/trials/hd21/)
- key papers: [PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd18-pet-guided-escalated-beacopp-lancet-2017/), [Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group](https://onco.cc/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/)
- roadmaps: [Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting](https://onco.cc/roadmaps/lymphoma-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/peter-borchmann.json